Why Novo Nordisk’s Semaglutide Trial Didn’t Slow Alzheimer’s

Why Novo Nordisk’s Trial Failed, and What Clinicians Really Need to Know

The Multi-Axis Metabolic Failure Behind Alzheimer’s